426463-09-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-5-Iodo-Pyridin-3-ylamine is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to form C-N bonds, which is crucial in the development of new molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-5-Iodo-Pyridin-3-ylamine serves as a vital component in the production of complex molecules for use in pesticides and other agrochemical products, contributing to the development of innovative and effective solutions for agricultural challenges.
Used in Synthetic Chemistry Research:
2-Chloro-5-Iodo-Pyridin-3-ylamine is utilized as a subject of interest in research, where its unique properties and reactivity are explored to expand the knowledge in synthetic chemistry and potentially discover new applications and reactions involving 2-CHLORO-5-IODO-PYRIDIN-3-YLAMINE.

InChI:InChI=1/C5H4ClIN2/c6-5-4(8)1-3(7)2-9-5/h1-2H,8H2

Upstream product

• 426463-05-0 2-chloro-5-iodo-3-nitro-pyridine 
• 6332-56-5 2-hydroxy-3-nitropyridine 
• 25391-59-7 5-iodo-3-nitro-pyridin-2-ol 
• 4214-75-9 2-amino-3-nitropyridine 
• 25391-57-5 5-Iodo-3-nitro-2-aminopyridine 

Downstream Products

• 97966-01-3 2,3-dichloro-5-iodopyridine 

Relevant academic research and scientific papers

Selective catalytic hydrogenation of nitro groups in the presence of activated heteroaryl halides

Chemoselective reduction of nitro groups in the presence of activated heteroaryl halides was achieved via catalytic hydrogenation with a commercially available sulfided platinum catalyst. The optimized conditions employ low temperature, pressure, and catalyst loading (0.1 mol % Pt) to afford heteroaromatic amines with minimal hydrodehalogenation byproducts.

Compounds and methods for promoting smoking cessation

Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states.

5-Azidoepibatidine: An Exceptionally Potent Photoaffinity Ligand for Neuronal α4β2 and α7 Nicotinic Acetylcholine Receptors

Racemic 5-azidoepibatidine [(+/-)-1] was synthesized via 5-aminoepibatidine as a candidate photoaffinity ligand with exceptionally high affinity at the mammalian neuronal nicotinic receptors (Ki values of 0.027 nM for α4β2 and 9.7 nM for α7) and excellent photoreactivity.

Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-2-(2′,3′-disubstituted 5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes: Epibatidine analogues

A number of 2′,3′-disubstituted epibatidine analogues were synthesized and evaluated in vitro for potency at nicotinic acetylcholine receptors (nAChRs) and in vivo for antinociception activity in the tail-flick and hot-plate models of acute pain and for their ability to affect core body temperature. Compounds that possessed electron-withdrawing groups (F, Cl, Br, and I) in both the 2′- and the 3′-positions showed affinities at the nAChR similar to epibatidine. However, in vivo efficacy did not correlate with affinity. 2-exo-(3′-Amino-2′-chloro-5′- pyridinyl)-7-azabicyclo-[2.2.1]heptane (2i), an epibatidine analogue possessing an electron-releasing amino group in the 3′-position, produced the highest affinity. Compound 2i was also the most selective epibatidine analogue with a Ki of 0.001 nM at αβ nAChRs, which is 26 times greater than that of epibatidine, and a αβ/α7 Ki ratio of 14 000, twice that of epibatidine. In vivo testing revealed that this compound potently inhibited nicotine-induced antinociception with AD50 values below 1 μg/kg. Surprisingly, this same compound was also an agonist at higher doses (ED50 ～20 μg/kg). Thus, the addition of the 3′-amino group to epibatidine confers potent antagonist activity to the compound with little effect on agonist activity. 2,3-Disubstituted epibatidine analogues possessing a 2′-amino group combined with a 3′-bromo or 3′-iodo group showed in vitro and in vivo nAChR properties similar to nicotine.